|
1
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classification of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Argilés JM, Busquets S, Stemmler B and
López-Soriano FJ: Cancer cachexia: Understanding the molecular
basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fearon KC, Glass DJ and Guttridge DC:
Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell
Metab. 16:153–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cooper C, Burden ST, Cheng H and
Molassiotis A: Understanding and managing cancer-related weight
loss and anorexia: Insights from a systematic review of qualitative
research. J Cachexia Sarcopenia Muscle. 6:99–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tuca A, Jimenez-Fonseca P and Gascón P:
Clinical evaluation and optimal management of cancer cachexia. Crit
Rev Oncol Hematol. 88:625–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Porporato PE: Understanding cachexia as a
cancer metabolism syndrome. Oncogenesis. 5:e2002016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Coss CC, Bohl CE and Dalton JT: Cancer
cachexia therapy: A key weapon in the fight against cancer. Curr
Opin Clin Nutr Metab Care. 14:268–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dodson S, Baracos VE, Jatoi A, Evans WJ,
Cella D, Dalton JT and Steiner MS: Muscle wasting in cancer
cachexia: Clinical implications, diagnosis, and emerging treatment
strategies. Annu Rev Med. 62:265–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Madeddu C, Mantovani G, Gramignano G and
Macciò A: Advances in pharmacologic strategies for cancer cachexia.
Expert Opin Pharmacother. 16:2163–2177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Molfino A, Amabile MI, Fanelli Rossi F and
Muscaritoli M: Novel therapeutic options for cachexia and
sarcopenia. Expert Opin Biol Ther. 16:1239–1244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Strasser F, Palmer JL, Schover LR, Yusuf
SW, Pisters K, Vassilopoulou-Sellin R, DeGracia B, Willey JS and
Bruera E: The impact of hypogonadism and autonomic dysfunction on
fatigue, emotional function, and sexual desire in male patients
with advanced cancer: A pilot study. Cancer. 107:2949–2957. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burney BO, Hayes TG, Smiechowska J,
Cardwell G, Papusha V, Bhargava P, Konda B, Auchus RJ and Garcia
JM: Low testosterone levels and increased inflammatory markers in
patients with cancer and relationship with cachexia. J Clin
Endocrinol Metab. 97:E700–E709. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basaria S, Coviello AD, Travison TG,
Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J,
Zhang A, et al: Adverse events associated with testosterone
administration. N Engl J Med. 363:109–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vigen R, O'Donnell CI, Barón AE, Grunwald
GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME,
Plomondon ME, et al: Association of testosterone therapy with
mortality, myocardial infarction, and stroke in men with low
testosterone levels. JAMA. 10:1829–1836. 2013. View Article : Google Scholar
|
|
15
|
Aikawa K, Miyawaki T, Hitaka T, Imai YN,
Hara T, Miyazaki J, Yamaoka M, Kusaka M, Kanzaki N, Tasaka A, et
al: Synthesis and biological evaluation of novel selective androgen
receptor modulators (SARMs). Part I. Bioorg Med Chem. 23:2568–2578.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dwarkasing JT, Boekschoten MV, Argilès JM,
van Dijk M, Busquets S, Penna F, Toledo M, Laviano A, Witkamp RF
and van Norren K: Differences in food intake of tumor-bearing
cachectic mice are associated with hypothalamic serotonin
signaling. J Cachexia Sarcopenia Muscle. 6:84–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ballarò R, Costelli P and Penna F: Animal
models for cancer cachexia. Curr Opin Support Palliat Care.
10:281–287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Talbert EE, Metzger GA, He WA and
Guttridge DC: Modeling human cancer cachexia in colon 26
tumor-bearing adult mice. J Cachexia Sarcopenia Muscle. 5:321–328.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ustünel I, Akkoyunlu G and Demir R: The
effect of testosterone on gastrocnemius muscle fibres in growing
and adult male and female rats: A histochemical, morphometric and
ultrastructural study. Anat Histol Embryol. 32:70–79. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Urban RJ: Growth hormone and testosterone:
Anabolic effects on muscle. Horm Res Paediatr. 76 Suppl 1:S81–S83.
2011. View Article : Google Scholar
|
|
21
|
De Gendt K and Verhoeven G: Tissue- and
cell-specific functions of the androgen receptor revealed through
conditional knockout models in mice. Mol Cell Endocrinol.
352:13–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aikawa K, Asano M, Ono K, Habuka N, Yano
J, Wilson K, Fujita H, Kandori H, Hara T, Morimoto M, et al:
Synthesis and biological evaluation of novel selective androgen
receptor modulators (SARMs) Part III: Discovery of
4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical
candidate. Bioorg Med Che. 25:3330–3349.. 2017. View Article : Google Scholar
|
|
23
|
Argiles JM, Lopez-Soriano FJ and Busquets
S: Counteracting inflammation: A promising therapy in cachexia.
Crit Rev Oncog. 17:253–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thompson RW, McClung JM, Baltgalvis KA,
Davis JM and Carson JA: Modulation of overload-induced inflammation
by aging and anabolic steroid administration. Exp Gerontol.
41:1136–1148. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Srinath R and Dobs A: Enobosarm (GTx-024,
S-22): A potential treatment for cachexia. Future Oncol.
10:187–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dillon EL, Basra G, Horstman AM, Casperson
SL, Randolph KM, Durham WJ, Urban RJ, Diaz-Arrastia C, Levine L,
Hatch SS, et al: Cancer cachexia and anabolic interventions: A case
report. J Cachexia Sarcopenia Muscle. 3:253–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Del Fabbro E, Garcia JM, Dev R, Hui D,
Williams J, Engineer D, Palmer JL, Schover L and Bruera E:
Testosterone replacement for fatigue in hypogonadal ambulatory
males with advanced cancer: A preliminary double-blind
placebo-controlled trial. Support Care Cancer. 21:2599–2607. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Vooqt HJ, Smith PH, Pavone-Macaluso M,
de Pauw M and Suciu S: Cardiovascular side effects of
diethylstilbestrol, cyproterone acetate, medroxyprogesterone
acetate and estramustine phosphate used for the treatment of
advanced prostatic cancer: Results from European Organization for
Research on Treatment of Cancer Trials 30761 and 30762. J Urol.
135:303–307. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ponnusamy S, Sullivan RD, Thiyagarajan T,
Tillmann H, Getzenberg RH and Narayanan R: Tissue selective
androgen receptor modulators (SARMs) increase pelvic floor muscle
mass in ovariectomized mice. J Cell Biochem. 118:640–646. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chisamore MJ, Gentile MA, Dillon GM, Baran
M, Gambone C, Riley S, Schmidt A, Flores O, Wilkinson H and Alves
SE: A novel selective androgen receptor modulator (SARM) MK-4541
exerts anti-androgenic activity in the prostate cancer xenograft
R-3327G and anabolic activity on skeletal muscle mass &
function in castrated mice. J Steroid Biochem Mol Biol. 163:88–97.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blanqué R, Lepescheux L, Auberval M, Minet
D, Merciris D, Cottereaux C, Clément-Lacroix P, Delerive P and
Namour F: Characterization of GLPG0492, a selective androgen
receptor modulator, in a mouse model of hindlimb immobilization.
BMC Musculoslelet Disord. 15:2912014. View Article : Google Scholar
|
|
32
|
Akita K, Harada K, Ichihara J, Takata N,
Takahashi Y and Saito K: A novel selective androgen receptor
modulator, NEP28, is efficacious in muscle and brain without
serious side effects on prostate. Eur J Pharmacol. 720:107–114.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang X, Allan GF, Tannenbaum P, Sbriscia
T, Linton O, Lai MT, Haynes-Johnson D, Bhattacharjee S, Lundeen SG
and Sui Z: Pharmacological characterization of an imidazolopyrazole
as novel selective androgen receptor modulator. J Steroid Biochem
Mol Biol. 134:51–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Narayanan R, Mohler ML, Bohl CE, Miller DD
and Dalton JT: Selective androgen receptor modulators in
preclinical and clinical development. Nucl Recept Signal.
6:e0102008.PubMed/NCBI
|
|
35
|
Narayanan R, Coss CC, Yepuru M, Kearbey
JD, Miller DD and Dalton JT: Steroidal androgens and nonsteroidal,
tissue-selective androgen receptor modulator, S-22, regulate
androgen receptor function through distinct genomic and nongenomic
signaling pathways. Mol Endocrinol. 22:2448–2465. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Crawford J, Prado CM, Johnston MA, Gralla
RJ, Taylor RP, Hancock ML and Dalton JT: Study design and rationale
for phase 3 clinical development program of enobosarm, a selective
androgen receptor modulator, for the prevention and treatment of
muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep.
18:372016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Garber K: No longer going to waste. Nat
Biotechnol. 34:458–461. 2016. View Article : Google Scholar : PubMed/NCBI
|
